Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1α-secreting glioblastoma

NK cells are promising effector cells for adjuvant immunotherapy of cancer. So far, several preclinical studies have shown the feasibility of gene-engineered NK cells, which upon expression of chimeric antigen receptors (CARs) are redirected to otherwise NK-cell resistant tumors. Yet, we reasoned th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother
Main Authors: Müller, Nadja, Michen, Susanne, Tietze, Stefanie, Töpfer, Katrin, Schulte, Alexander, Lamszus, Katrin, Schmitz, Marc, Schackert, Gabriele, Pastan, Ira, Temme, Achim
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4428685/
https://ncbi.nlm.nih.gov/pubmed/25962108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0000000000000082
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados